Formulation Design and Optimization for the Improvement of Nystatin-Loaded Lipid Intravenous Emulsion
| dc.contributor.author | Marín-Quintero, D. | |
| dc.contributor.author | Fernández Campos, Francisco | |
| dc.contributor.author | Calpena Campmany, Ana Cristina | |
| dc.contributor.author | Montes López, María Jesús | |
| dc.contributor.author | Clares Naveros, Beatriz | |
| dc.contributor.author | Pozo Carrascosa, Alfonso del | |
| dc.date.accessioned | 2025-01-31T09:44:32Z | |
| dc.date.available | 2025-01-31T09:44:32Z | |
| dc.date.issued | 2013-11-22 | |
| dc.date.updated | 2025-01-31T09:44:32Z | |
| dc.description.abstract | ABSTRACT: Nystatin (NYS) is a polyene macrolide with broad antifungal spectrum restricted to topical use owing to its toxicity upon systemic administration. The aims of thiswork were the design, development, and optimization ofNYS-loaded lipid emulsion for intravenous administration. A closed circuit system was designed to apply ultrasound during the elaboration of the lipid intravenous emulsions (LIEs). Additionally, a comparison with the commercially available Intralipid R 20% was also performed.Manufacturing conditions were optimized by factorial design. Formulations were evaluated in terms of physicochemical parameters, stability, release profile, and antimicrobial activity. The average droplet size, polydispersity index, zeta-potential, pH, and volume distribution values ranged between 192.5 and 143.0 nm, 0.170 and 0.135, −46 and −44 mV, 7.11 and 7.53, 580 and 670 nm, respectively. The selected NYS-loaded LIE (NYS-LIE54) consisted of soybean oil (30%), soybean lecithin (2%), solutol HSR 15 (4%), and glycerol (2.25%) was stable for at least 60 days. In vitro drug release studies of this formulation suggested a sustained-release profile. Equally, NYS-LIE54 showed the best antimicrobial activity being higher than the free drug. Thus, it could be a promising drug delivery system to treat systemic fungal infections. C 2013 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci Keywords: drug design; nystatin; lipids; emulsion; injectables; surfactants; candida; aspergillus; mathematical model | |
| dc.format.extent | 9 p. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.idgrec | 628184 | |
| dc.identifier.issn | 0022-3549 | |
| dc.identifier.uri | https://hdl.handle.net/2445/218304 | |
| dc.language.iso | eng | |
| dc.publisher | Wiley | |
| dc.relation.isformatof | Versió postprint del document publicat a: | |
| dc.relation.ispartof | Journal of Pharmaceutical Sciences, 2013, vol. 102, num.11, p. 4015-4023 | |
| dc.rights | (c) The American Pharmacists Association, 2013 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.source | Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica) | |
| dc.subject.classification | Lípids | |
| dc.subject.classification | Emulsions | |
| dc.subject.other | Lipids | |
| dc.subject.other | Emulsions | |
| dc.title | Formulation Design and Optimization for the Improvement of Nystatin-Loaded Lipid Intravenous Emulsion | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/acceptedVersion |
Fitxers
Paquet original
1 - 1 de 1